Skip to Main Content

Whisper numbers can be cruel.

Just ask Amarin (AMRN), which reported another strong quarter for Vascepa, its heart drug derived from fish oil. Sales totaled $73 million in the first quarter, a 67% increase from the year-ago period. Vascepa prescriptions — and revenue — are surging now that the drug has been shown to significantly lower the risk of death and other adverse cardiovascular events.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED